InteRNA is a Dutch biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer. Using its leading microRNA (miRNA) discovery and functional validation platform, InteRNA is developing a pipeline of proprietary preclinical miRNA drug candidates targeting key processes in cancer initiation and progression. Enabled with a 3rd generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously. With this approach, we address the high need for novel therapeutics with improved efficacy and less drug resistance that really benefit cancer patients.
miRNAs provide a unique simultaneous regulation of multiple mRNA targets and as such
1. block activated cancer signaling pathways, and
2. prevent activation of alternative cancer signaling pathways,
leading to improved long term control of advanced tumors and reduced relapse rates.